ADRO Aduro Biotech Inc.

11.00
-0.15  -1%
Previous Close 11.15
Open 11.10
Price To book 3.19
Market Cap 820736939
Shares 74,612,449
Volume 367,398
Short Ratio 18.19
Av. Daily Volume 366,410

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation noted June 29, 2017.
CRS-207 with KEYTRUDA
Gastric cancer
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
Epacadostat and CRS-207 - SEASCAPE
Ovarian cancer
Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
CRS-207 with pembrolizumab
Mesothelioma - cancer

Latest News

  1. Aduro Biotech to Present at Three Investor Conferences in the Second Half of September
  2. Why Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report?
  3. ETFs with exposure to Aduro BioTech, Inc. : September 7, 2017
  4. Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
  5. Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : September 1, 2017
  6. Aduro Biotech to Present at Three Investor Conferences in the First Half of September
  7. Aduro BioTech, Inc. – Value Analysis (NASDAQ:ADRO) : August 23, 2017
  8. Aduro BioTech, Inc. breached its 50 day moving average in a Bearish Manner : ADRO-US : August 11, 2017
  9. Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents
  10. Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top
  11. Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference
  12. Aduro Biotech reports 2Q loss
  13. Aduro Biotech Reports Second Quarter 2017 Financial Results
  14. Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017
  15. Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer
  16. Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma
  17. Aduro Starts Phase II Combo Study with CRS-207 & Keytruda
  18. Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma
  19. Can Aduro BioTech (ADRO) Run Higher on Strong Earnings Estimate Revisions?